Scholar Rock Holding Corporation (SRRK)
| Market Cap | 7.04B +112.4% |
| Revenue (ttm) | n/a |
| Net Income | -408.59M |
| EPS | -3.36 |
| Shares Out | 121.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 809,720 |
| Open | 58.75 |
| Previous Close | 59.26 |
| Day's Range | 57.17 - 59.30 |
| 52-Week Range | 27.07 - 61.76 |
| Beta | 0.67 |
| Analysts | Strong Buy |
| Price Target | 60.75 (+5.1%) |
| Earnings Date | Aug 6, 2026 |
About SRRK
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company’s novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFβ) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or laten... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for SRRK stock is "Strong Buy." The 12-month stock price target is $60.75, which is an increase of 5.10% from the latest price.
News
Scholar Rock to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseas...
Scholar Rock price target raised to $64 from $58 at Wedbush
Wedbush raised the firm’s price target on Scholar Rock (SRRK) to $64 from $58 and keeps an Outperform rating on the shares.
Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission
Scholar Rock said on Friday it withdrew its European application for the experimental spinal muscular atrophy drug and plans to resubmit it with a different manufacturing site after issues at a Novo...
Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance
Scholar Rock (SRRK) announced it has removed Catalent Indiana (NVO) as a commercial fill-finish facility from its apitegromab Biologics License Application for the treatment of spinal muscular atrophy...
Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseas...
Scholar Rock price target raised to $63 from $56 at JPMorgan
JPMorgan analyst Tessa Romero raised the firm’s price target on Scholar Rock (SRRK) to $63 from $56 and keeps an Overweight rating on the shares. The firm updated the company’s…
Scholar Rock facioscapulohumeral muscular dystrophy treatment gets orphan status
Scholar Rock’s (SRRK) apitegromab was granted FDA orphan designation as a treatment of facioscapulohumeral muscular dystrophy, according to a post to the agency’s website.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 51,947 shares of its common sto...
Scholar Rock Holding Transcript: Canaccord Genuity's 46th Annual Growth Conference
Scholar Rock drops Catalent facility from marketing application for muscle weakness drug
Scholar Rock said on Friday it would remove Catalent's Indiana manufacturing facility from its application seeking FDA approval for a rare neuromuscular disease drug.
Scholar Rock to remove Catalent Indiana facility from apitegromab BLA
Scholar Rock (SRRK) announced that the FDA review of the apitegromab biologics license application, or BLA, for the treatment of children and adults with spinal muscular atrophy, or SMA, is…
Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseas...
Scholar Rock price target raised to $76 from $70 at BMO Capital
BMO Capital raised the firm’s price target on Scholar Rock (SRRK) to $76 from $70 and keeps an Outperform rating on the shares. Scholar Rock’s CMC progress and confidence ahead…
Scholar Rock price target raised to $60 from $58 at Citi
Citi raised the firm’s price target on Scholar Rock (SRRK) to $60 from $58 and keeps a Buy rating on the shares.
Scholar Rock Holding Earnings Call Transcript: Q2 2026
Apitegromab is on track for FDA approval by September 30, 2026, with two independent fill-finish facilities ensuring launch readiness and robust commercial preparations in the U.S. and Europe. Financials remain strong, with $492 million in cash and disciplined capital allocation.
Scholar Rock Holding Earnings release: Q2 2026
Scholar Rock Holding released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Scholar Rock Holding Quarterly report: Q2 2026
Scholar Rock Holding has published its Q2 2026 quarterly earnings report on August 6, 2026.
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseas...
Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additi...
Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026
Scholar Rock said on Monday a European Union opinion on its experimental spinal muscular atrophy treatment could be pushed to later this year, as regulators await the U.S. FDA's classification of a ...
Scholar Rock provides update on timing of CHMP opinion for apitegromab MAA
Scholar Rock (SRRK) provided an update on the anticipated timing of a Committee for Medicinal Products for Human Use, CHMP, opinion for the apitegromab marketing authorisation application, MAA, for ch...
Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseas...
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026, before the financial markets open....
Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additi...
Scholar Rock Holding Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Apitegromab, a first-in-class myostatin inhibitor, is poised for broad SMA market entry in 2026 following strong phase III results and regulatory progress. Manufacturing issues have been addressed, and a global launch is planned, with additional pipeline programs advancing in FSHD and other neuromuscular diseases.